Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
  • C07F7/1896—Compounds having one or more Si-O-acyl linkages
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
  • C07D499/87—Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/429—Thiazoles condensed with heterocyclic ring systems
  • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
  • Y02P20/00—Technologies relating to chemical industry
  • Y02P20/50—Improvements relating to the production of bulk chemicals
  • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

• the present invention relates to methods of forming methyl penam derivatives, in particular methyl penam derivatives suitable for use with ⁇ -lactam antibiotics as ⁇ - lactamase inhibitors.
• Emergence and dissemination of resistance is an inevitable consequence of the evolutionary dynamic set in motion by the introduction of antibiotics, irrespective of structural class or mode of action (Shapiro S. 2013. Speculative strategies for new antibacterials: all roads should not lead to Rome. J. Antibiot. 66: 371-386).
• Spread of resistance amongst clinically relevant pathogens has had an especially strong impact on the value of ⁇ -lactam antibiotics, heretofore regarded as very safe and efficacious therapies for serious bacterial infections.
• WO 2008/010048 discloses ⁇ -lactamase inhibitors having the following formula:
• the ⁇ -lactamase inhibitors disclosed in WO 2008/010048 includes the compound (2 l S , ,3,S',5ii)-3-methyl-3-((3-methyl-lH-l,2,3-triazol-3-ium-l-yl)methyl)-7-oxo-4-thia-l- azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide (formula A):
• the R group is formed by a substitution reaction, for example by reaction with methyl iodide in the case of formula (A).
• WO 2008/010048 discloses formation of amorphous compounds isolated by filtering and lyophilisation.
• the invention provides a method of forming a compound of formula
• R 1 in each occurrence is independently selected from H, halogen, amino, C 1-5 alkyl, C 1-5 alkenyl and Ci_5 alkynyl;
• R 2 in each occurrence is independently selected from H, halogen, amino, Q_5 alkyl, Ci -5 alkenyl and C 1-5 alkynyl;
• R 4 is C 1-5 alkyl
• R 6 is a Ci_5 fluoroalkyl
• PG is a protecting group, the method comprising the step of reacting a compound of formula (Ila) with a compound of formula (VIII):
• the invention provides a method of forming a compound of formula (IV):
• R in each occurrence is independently selected from H, halogen, amino, C 1-5 alkyl, C 1-5 alkenyl and C 1-5 alkynyl; R in each occurrence is independently selected from H, halogen, amino, C 1-5 alkyl, C 1-5 alkenyl and C 1-5 alkynyl; and R 4 is C 1-5 alkyl; the method comprising the step of reacting a compound of formula (III) with a 2- ethylhexanoate salt:
• the compound of formula (III) reacted in the second aspect of the invention may be formed by the method described in the first aspect in the case where PG of formula (Ilia) is a group of formula SiR 3.
• the invention provides a method of forming a compound of formula (II):
• R 1 in each occurrence is independently selected from H, halogen, amino, Ci_5 alkyl, C 1-5 alkenyl and C 1-5 alkynyl; R in each occurrence is independently selected from H, halogen, amino, C 1-5 alkyl, C 1-5 alkenyl and C 1-5 alkynyl; and R in each occurrence is independently selected from the group consisting of C 1-5 alkoxy and C 1-10 hydrocarbyl, optionally C 1-5 alkoxy, C 1-5 alkyl, phenyl, and phenyl-Ci-4 alkyl; the method comprising the step of reacting a compound of formula (I) with less than a molar equivalent of a compound of formula (V)
• the compound of formula (II) formed by the method of the third aspect may be used in the reaction of the first aspect in the case where PG of formula (Ila) is a group of formula
• Figure 1 is an XRPD spectrum of a crystalline compound prepared by a process according to an embodiment of the invention
• Figure 2 is a Raman spectrum of a crystalline crystalline compound prepared by a process according to an embodiment of the invention.
• Figure 3 is a scanning electron microscope image of a crystalline crystalline compound prepared by a process according to an embodiment of the invention.
• Figure 4 is a LCMS spectrum of the product of a reaction between (2S,3S,5R)-3-methy ⁇ - 3-((3-methyl- 1 H- 1 ,2,3 -triazol-3 -ium- 1 -yl)methyl)-7-oxo-4-thia- 1 - azabicyclo[3.2.0]heptane-2-carboxylate 4,4-dioxide and ⁇ , ⁇ -bis trimethylsilylacetamide.
• R 1 in each occurrence is independently selected from H, halogen, amino, C 1-5 alkyl, C 1-5 alkenyl and C 1-5 alkynyl;
• R in each occurrence is independently selected from H, halogen, amino, C 1-5 alkyl, C 1-5 alkenyl and Ci_5 alkynyl;
• R in each occurrence is independently selected from Ci_io hydrocarbyl and Ci_5 alkoxy, optionally C 1-5 alkyl, C 1-5 alkoxy, phenyl, and phenyl-Ci-4 alkyl;
• R 4 is C 1-5 alkyl
• X is an anion
• each R 1 is H.
• each R is H.
• R 4 is methyl
• the carboxyl group of the compound of formula (I) is silylated in step (i).
• silylation is carried out using an amide of formula (V):
• each R is methyl.
• each R is methyl.
• a preferred compound of formula (V) is ⁇ , ⁇ -bis trimethylsilylacetamide.
• the reaction may be carried out in a polar aprotic solvent, optionally a chlorinated solvent such as dichloromethane.
• the compound of formula (I) may be reacted with at least a molar equivalent of the compound of formula (V), optionally a molar excess of the compound of formula (V).
• both of the silyl groups of the compound of formula (V) may be utilized in silylation of the compound of formula (I).
• the compound of formula (I) is reacted with less than a molar equivalent of the compound of formula (V), optionally no more than 0.9 molar equivalents, optionally no more than 0.8, 0.7 or 0.6 molar equivalents.
• the compound of formula (V) may be added to the reaction mixture in a single addition or may be added in two or more portions.
• the alkylation of step (ii) may be a C 1-5 alkylation, preferably a methylation.
• Alkylation may be carried out with any suitable alkylating group, preferably a compound of formula (VI):
• R 4 is a Ci_5 alkyl group and X is a leaving group.
• R 4 is methyl.
• X is selected from the group consisting of chloride, bromide, iodide, and sulfonates.
• exemplary sulfonates are groups of formula (VII):
• R 6 is selected from aryl, optionally phenyl, that may be unsubstituted or substituted with one or more substituents, and Ci_5 alkyl wherein one or more H atoms of the Ci-5 alkyl group may be replaced with F, and * represents a bond to R 1 .
• exemplary groups of formula (VII) include trifluoromethanesulfonate (triflate) and p- toluenesulfonate (tosylate).
• R 6 is C1-5 alkyl wherein one or more H atoms of the C1-5 alkyl group are replaced with F. More preferably, R 6 is trifluoromethyl.
• the reaction may be carried out any temperature up to the boiling point of the reaction mixture at atmospheric pressure.
• a fluorinated alkyl R 6 may allow the alkylation step to proceed at low temperature, optionally at a temperature of less than 20°C, optionally less than 10°C, optionally at about 0°C.
• the present inventors have further found that use of a fluorinated alkyl R 6 allows for a significantly faster reaction than use of halogen groups R 6 .
• the silylated compound formed in step (i) is not isolated before the alkylation step.
• Compounds (II) and (III) of Scheme 1 carry a silyl protecting group protecting the carboxyl group of these compounds, however it will be appreciated that the protecting group for reaction step (ii) may be another protecting group PG.
• the skilled person will be aware of other protecting groups suitable for protecting the carboxyl group of compounds of formula (II) during the alkylation of step (ii).
• Exemplary protecting groups PG other than the group of formula SiR 3 include allyl, which may be removed following alkylation using a metal 2-ethylhexanoate and Pd(0); groups which may be removed by hydrogenolysis, for example benzyl, benzidryl and p-nitrobenzyl; and groups that can be removed with a base, for example fluorenylmethyl. Further protecting groups for protection of a carboxyl are described in Theodora W. Greene and Peter G. M. Wuts, "Protective Groups in Organic Synthesis", Second Edition, John Wiley & Sons, Inc., the contents of which are incorporated herein by reference.
• the present inventors have found that the silyl group of the compound of formula (III) may be removed by treatment with 2-ethylhexanoates to yield a solid product, and treatment with a 2-ethylhexanoate can yield crystals of the compound of formula (IV).
• treatment with methanol, ethanol or isopropanol or the bases sodium hydroxide or sodium acetate yields a non- solid product, such as an oil, a gum or a gel, that cannot be readily be converted to a solid form.
• Exemplary 2-ethylhexanoates are metal 2-ethylhexanoates.
• Suitable metals include alkali and alkali earth metals, for example lithium, sodium, potassium, calcium and magnesium.
• the compound of formula (III) is not isolated before the desilylation step.
• the compound of formula (III) may be added to a solution of a metal 2-ethylhexanoate to produce crystals of the compound of formula (IV).
• exemplary solvents for the solution are alcohols, preferably ethanol.
• the compound of formula (IV) may be amorphous or crystalline. Crystalline compounds of formula (IV) may be easier to handle and more stable than amorphous compounds.
• Methods of forming crystalline compounds of formula (IV) include, without limitation, dissolving or dispersing an amorphous compound of formula (IV) in a solvent or solvent mixture and inducing formation of crystals by adding one or more antisolvents to the solution or dispersion; cooling the solution or dispersion; and / or adding a crystal of a compound of formula (IV) to provide a nucleation point for crystallisation.
• An "antisolvent” as used herein means a liquid in which the compound of formula (IV) has a lower solubility than a solvent of the solution or dispersion that the antisolvent is added to.
• Compounds of formula (IV) may be used in a pharmaceutical composition with one or more antibiotics, and may comprise one or more conventional pharmaceutically acceptable excipient(s).
• Compounds of formula (IV) may be administered in a composition with an antibiotic, or an antibiotic and a compound of formula (IV) may be administered separately.
• a pharmaceutical composition as described herein may be in an injectable form for intravenous injection.
• the composition may contain stabilizing agents.
• the composition may be in suitable sterile solid form ready for reconstitution to form an injectable solution, for example a saline solution.
• antibiotics are ⁇ -lactam antibiotics, in particular penicillins and
• cephalosporins and may be selected from Amoxicillin, Ampicillin, Apalcillin, Azlocillin, Bacampicillin, Carbenacillin, Cloxacillin, Dicl oxacillin, Flucloxacillin, Lenampicillin, Mecillinam, Methacillin, Mezlocillin, Nafcillin, Oxacillin, Penicillin G, Penicillin V, Piperacillin, Temocillin, Ticarcillin, Aztreonam, BAL30072, Carumonam, PTX2416, Tigemonam, Cefaclor, Cefadroxil, Cefalexin, Cefalotin, Cefamandole, Cefapirin, Cefazolin, Cefbuperazone, Cefdinir, Cefepime, Cefetamet, Cefixime, Cefmenoxime, Cefmetazole, Cefrninox, Cefonicid, Cefoperazone, Cefo
• the antibiotic may be selected from aminoglycosides: Amikacin, Arbekacin, Apramycin, Dibekacin, Gentamicin, Isepamicin, Kanamycin, Neomycin, Netilmicin, Plazomicin, Sisomicin, Spectinomyin, Streptomycin, Tobramycin or derivatives thereof.
• the antibiotic may be selected from quinolones: Cinoxacin, Ciprofloxacin, Enofloxacin, Gatifloxacin, Gemifloxacin, Levofloxacin, Moxifloxacin, Nalidixic acid, Norfloxacin, Oxafloxacin, or derivatives thereof.
• the antibiotic may be selected from antimicrobial peptides, for example Colistin, Polymyxin B or derivatives thereof.
• a pharmaceutical composition as described herein may comprise only one or more than one antibiotic.
• a pharmaceutical composition containing a crystalline compound of formula (I) may contain or be co-administered with bactericidal or permeability-increasing-g protein product (BPI) or efflux pump inhibitors to improve activity against gram negative bacteria and bacteria resistant to antimicrobial agents.
• BPI permeability-increasing-g protein product
• Antiviral, antiparasitic, antifungal agents may also be administered in combination with the inhibitor compounds.
• the pharmaceutical composition may contain complexing agents or anticoagulants, antioxidants, stabilizers, aminoglycosides, pharmaceutically acceptable salts or the like or mixtures thereof.
• the pharmaceutical composition may contain ⁇ -lactam antibiotics, preferably penicillins, cephalosporins, carbapenem, monobactams, more preferably piperacillin, cefepime; ceftriaxone; meropenem, aztreonam.
• ⁇ -lactam antibiotics preferably penicillins, cephalosporins, carbapenem, monobactams, more preferably piperacillin, cefepime; ceftriaxone; meropenem, aztreonam.
• the pharmaceutical composition may contain buffers, for example sodium citrate, sodium acetate, sodium tartrate, sodium carbonate, sodium bicarbonate,
• morpholinopropanesulfonic acid other phosphate buffers and the like and chelating agents like ethylenediaminetetraacetic acid (EDTA) , diethylenetriaminepentaacetic acid, hydroxyethylenediaminetriacetic acid, nitrilotriacetic acid, 1 ,2- diaminocyclohexanetetraacetic acid, bis(2-aminoethyl)ethyleneglycoltetraacetic acid, 1 ,6-hexamethylenediaminetetraacetic acid and the like or pharmaceutically acceptable salts thereof.
• EDTA ethylenediaminetetraacetic acid
• a pharmaceutical composition as described herein may be administered to a human or warm-blooded animal by any suitable method, and preferably by intravenous injection.
• Figure 1 is an XRPD spectrum of crystalline Compound (4) acquired in transmission mode on a Rigaku MiniFlex 600 using the following conditions:
• Wavelength CuKalfa lambda 1.541862A
• Figure 2 is a Raman spectrum of crystalline Compound (4) run on a Jasco RFT-600: light source : Nd-YAG ( 1064 nm : exciting wavelength).
• Figure 3 is a scanning electron microscope image of crystalline Compound (4) using a JEOL JSM 5500 LV scanning electron microscope, operating at 30 kV in low vacuum (30 Pa) with the backscattered electron technique. Comparative Example 1
• Silylation step (i) of Scheme 2 was performed using varying molar ratios of the silylating agent ⁇ , ⁇ -bis trimethylsilylacetamide (BSA).
• the quantity of this impurity can be greatly reduced by using a lower molar equivalent of BSA.
• Methylation step (ii) of Scheme 2 was performed using iodomethane, as disclosed in WO 2008/010048 ⁇ and methyl tosylate.
• iodomethane as disclosed in WO 2008/010048 ⁇ and methyl tosylate.
• reactions using methyl triflate are much faster, provide a higher yield, can be conducted at much lower temperatures and require a smaller amount of methylating agent than either methyl tosylate or iodomethane.
• use of methyl triflate at relatively low temperature avoids safety issues arising from toxicity of methylating agents used at relatively high temperature, such as use of iodomethane at or above its boiling point.
• Desilylation step (iii) of Scheme 2 was attempted using a range of alcohols such as methanol, ethanol and 2-propanol. This approach led to recovery of product in form of oil or gel. These oils or gel were treated with different solvents such ACN, THF and Acetone, which gave complete dissolution and no solid material could be recovered. Use of diethyl ether, toluene, hexane and, heptane led to other gels and no solid could be recovered. Bases were tried to adjust pH to neutrality. For this purpose NaOH solution, AcONa (as is and in aqueous and organic solutions) and Sodium-2-ethylhexanoate (as is or in organic solutions) were tested.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Steroid Compounds (AREA)
• Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
• Feed For Specific Animals (AREA)

Priority Applications (26)

Applications Claiming Priority (2)

Publications (2)

Family

ID=51134924

Family Applications (1)

Country Status (29)

Families Citing this family (1)

Family Cites Families (4)

• 2014
  • 2014-05-15 GB GBGB1408649.0A patent/GB201408649D0/en not_active Ceased
• 2015
  • 2015-05-14 DK DK15726552.1T patent/DK3143028T3/da active
  • 2015-05-14 CN CN201580024639.6A patent/CN106459086B/zh active Active
  • 2015-05-14 BR BR112016026074-0A patent/BR112016026074B1/pt active IP Right Grant
  • 2015-05-14 ES ES15726552T patent/ES2699644T3/es active Active
  • 2015-05-14 AU AU2015261416A patent/AU2015261416B2/en active Active
  • 2015-05-14 US US15/311,146 patent/US9963465B2/en active Active
  • 2015-05-14 RS RS20190558A patent/RS58748B1/sr unknown
  • 2015-05-14 CR CR20160580A patent/CR20160580A/es unknown
  • 2015-05-14 EP EP15726552.1A patent/EP3143028B1/en active Active
  • 2015-05-14 LT LTEP15726552.1T patent/LT3143028T/lt unknown
  • 2015-05-14 KR KR1020167032608A patent/KR102329186B1/ko active Active
  • 2015-05-14 RS RS20181383A patent/RS58430B1/sr unknown
  • 2015-05-14 EP EP18195989.1A patent/EP3441395A1/en not_active Withdrawn
  • 2015-05-14 DK DK17168966.4T patent/DK3231806T3/da active
  • 2015-05-14 SG SG11201609494YA patent/SG11201609494YA/en unknown
  • 2015-05-14 ES ES17168966T patent/ES2725675T3/es active Active
  • 2015-05-14 TR TR2019/06867T patent/TR201906867T4/tr unknown
  • 2015-05-14 LT LTEP17168966.4T patent/LT3231806T/lt unknown
  • 2015-05-14 SI SI201530738T patent/SI3231806T1/sl unknown
  • 2015-05-14 HR HRP20182065TT patent/HRP20182065T1/hr unknown
  • 2015-05-14 WO PCT/EP2015/060733 patent/WO2015173378A2/en not_active Ceased
  • 2015-05-14 JP JP2017512434A patent/JP6613303B2/ja active Active
  • 2015-05-14 PE PE2016002171A patent/PE20161433A1/es unknown
  • 2015-05-14 PT PT15726552T patent/PT3143028T/pt unknown
  • 2015-05-14 MX MX2016014644A patent/MX378875B/es unknown
  • 2015-05-14 PL PL17168966T patent/PL3231806T3/pl unknown
  • 2015-05-14 HU HUE17168966 patent/HUE044511T2/hu unknown
  • 2015-05-14 PL PL15726552T patent/PL3143028T3/pl unknown
  • 2015-05-14 EA EA201692306A patent/EA033494B1/ru unknown
  • 2015-05-14 EP EP17168966.4A patent/EP3231806B1/en active Active
  • 2015-05-14 CA CA2945900A patent/CA2945900C/en active Active
  • 2015-05-14 SI SI201530509T patent/SI3143028T1/sl unknown
  • 2015-05-14 EA EA201991629A patent/EA201991629A3/ru unknown
  • 2015-05-14 PT PT17168966T patent/PT3231806T/pt unknown
• 2016
  • 2016-10-29 EC ECIEPI201685143A patent/ECSP16085143A/es unknown
  • 2016-11-08 IL IL248834A patent/IL248834B/en active IP Right Grant
  • 2016-11-11 CL CL2016002880A patent/CL2016002880A1/es unknown
• 2018
  • 2018-07-19 CL CL2018001961A patent/CL2018001961A1/es unknown
  • 2018-12-05 CY CY181101299T patent/CY1120957T1/el unknown
• 2019
  • 2019-05-06 HR HRP20190830TT patent/HRP20190830T1/hr unknown
  • 2019-05-09 CY CY20191100501T patent/CY1121756T1/el unknown

Also Published As

Similar Documents

Legal Events